Latest Evidence in Pulmonary Embolism Management

1,974 patients with acute symptomatic PE randomized to outpatient management criteria using Hestia decision rule versus PESI score class I-II (or sPESI of 0). Patients were selected for outpatient discharge within 24 hours across 26 French emergency departments.

Outpatient rate was higher with Hestia (38.7%) versus PESI (37.1%). The primary composite endpoint (recurrent VTE, major bleeding, or all-cause mortality at 30 days) occurred in 1.3% vs 1.1% (difference 0.2%; 95% CI −0.8 to 1.3%), confirming non-inferiority. Hestia criteria identified a larger proportion of outpatient-eligible patients without compromising safety.

Guideline relevance: Supports the 2026 Class 2a recommendation for Hestia criteria in outpatient PE management decisions.

Roy PM, et al. Eur Heart J. 2021;42(33):3146-3154.

5,395 patients with acute symptomatic DVT or PE randomized to apixaban (10 mg twice daily for 7 days, then 5 mg twice daily) versus conventional enoxaparin/warfarin therapy for 6 months. No parenteral lead-in was required for the apixaban arm.

Apixaban was non-inferior for recurrent VTE or VTE-related death (2.3% vs 2.7%; RR 0.84; 95% CI 0.60-1.18). Major bleeding was significantly lower with apixaban (0.6% vs 1.8%; RR 0.31; 95% CI 0.17-0.55) — a 54% relative reduction. Major plus clinically relevant non-major bleeding was also significantly reduced (4.3% vs 9.7%).

Guideline relevance: Foundational trial supporting apixaban as a first-line DOAC for PE (COR 1, LOE A) in the 2026 guideline.

Agnelli G, et al. N Engl J Med. 2013;369(9):799-808.

4,832 patients with acute symptomatic PE randomized to rivaroxaban (15 mg twice daily for 21 days, then 20 mg once daily) versus enoxaparin bridging to vitamin K antagonist. Treatment duration was 3, 6, or 12 months per investigator and patient choice.

Recurrent VTE occurred in 2.1% vs 1.8% (HR 1.12; 95% CI 0.75-1.68), meeting non-inferiority. Clinically relevant bleeding occurred in 10.3% vs 11.4% (HR 0.90; 95% CI 0.76-1.07). Major bleeding was significantly lower with rivaroxaban (1.1% vs 2.2%; HR 0.49; 95% CI 0.31-0.79).

Guideline relevance: Foundational trial supporting rivaroxaban as a first-line DOAC for PE. Rivaroxaban requires no parenteral lead-in, simplifying treatment initiation.

Büller HR, et al. N Engl J Med. 2012;366(14):1287-1297.

1,006 patients with intermediate-risk PE (confirmed RV dysfunction on echo or CT plus positive troponin) randomized to weight-based tenecteplase (30-50 mg IV over 5-10 seconds) plus heparin versus heparin plus placebo.

The primary endpoint (all-cause death or hemodynamic collapse within 7 days) occurred in 2.6% vs 5.6%(OR 0.44; 95% CI 0.23-0.87; p=0.02), favoring tenecteplase. However, major extracranial bleeding was 6.3% vs 1.2% (p<0.001) and stroke occurred in 2.4% vs 0.2% — including 2.0% intracranial hemorrhage in the thrombolysis arm, nearly all fatal or severely disabling.

Guideline relevance: Established the efficacy-versus-bleeding tradeoff for systemic thrombolysis in intermediate-risk PE, supporting a reserved role for decompensating patients rather than routine use.

Meyer G, et al. N Engl J Med. 2014;370(15):1402-1411.

PEITHO-2 evaluated weight-based reduced-dose tenecteplase in intermediate-high-risk PE patients. HoT-PE randomized 250 patients with intermediate-risk PE (RV dysfunction plus troponin elevation) to half-dose alteplase (50 mg) versus full-dose (100 mg) with heparin continuation in both arms.

HoT-PE demonstrated equivalent 30-day clinical success (reduction in RV/LV ratio ≥25% or complete clot burden reduction) with half-dose versus full-dose: 96.0% vs 94.4%. Major bleeding was 2.4% vs 9.6% with half versus full dose. Intracranial hemorrhage was 0% vs 2.4% in HoT-PE — a clinically critical difference.

Guideline relevance: Provides rationale for reduced-dose alteplase when systemic thrombolysis is chosen for intermediate-high-risk PE, as incorporated into the 2026 advanced therapy framework.

Sharifi M, et al. (HoT-PE). N Engl J Med. 2018;379:511-512. Meyer G, et al. (PEITHO-2). Eur Heart J. 2022.

1,155 patients with cancer-associated VTE (DVT or PE) randomized to apixaban (10 mg twice daily for 7 days, then 5 mg twice daily) versus dalteparin (200 IU/kg for 1 month then 150 IU/kg) for 6 months. Gastrointestinal and genitourinary cancers were not excluded.

Recurrent VTE occurred in 5.6% vs 7.9% (HR 0.63; 95% CI 0.37-1.07), meeting the pre-specified non-inferiority margin. Major bleeding was 3.8% vs 4.0% (HR 0.82; 95% CI 0.40-1.69) — not significantly different, and crucially, major GI bleeding was not significantly increased with apixaban (1.9% vs 1.4%).

Guideline relevance: Together with SELECT-D, established apixaban as an alternative to LMWH in cancer VTE, particularly for non-GI/GU malignancies per the 2026 guideline Special Populations section.

Agnelli G, et al. N Engl J Med. 2020;382(17):1599-1607.

406 patients with cancer-associated VTE randomized to rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily) versus dalteparin for 6 months. Colorectal and GI cancers were included.

Recurrent VTE: 4% vs 11% (HR 0.43; 95% CI 0.19-0.99) with rivaroxaban — a 57% relative reduction. Clinically relevant non-major bleeding was higher with rivaroxaban (13% vs 4%), driven primarily by GI bleeding in colorectal cancer patients. No significant difference in major bleeding overall (6% vs 4%).

Guideline relevance: Demonstrated VTE efficacy superiority with rivaroxaban but highlighted the GI bleeding concern in luminal GI cancers, informing the guideline recommendation to prefer LMWH in high-risk GI/GU malignancies.

Young AM, et al. J Clin Oncol. 2018;36(20):2017-2023.

1,050 patients with cancer-associated VTE randomized to edoxaban (60 mg once daily; 30 mg in patients with CrCl 30-50 mL/min or weight ≤60 kg or P-gp inhibitors) versus dalteparin for at least 6 months. Initial 5-10 days of LMWH required before edoxaban initiation.

Primary composite outcome (recurrent VTE or major bleeding): 12.8% vs 13.5%(HR 0.97; 95% CI 0.70-1.36), meeting non-inferiority (p=0.006). Recurrent VTE was lower with edoxaban (7.9% vs 11.3%; HR 0.71), while major bleeding was higher with edoxaban (6.9% vs 4.0%; HR 1.77), driven predominantly by upper GI bleeding in patients with GI cancers.

Guideline relevance: Third major cancer-VTE DOAC trial confirming the class effect — DOACs are preferred over LMWH for most cancer VTE except high-risk luminal GI/GU malignancies.

Raskob GE, et al. N Engl J Med. 2018;378(7):615-624.

150 patients with massive (31%) or submassive (69%) PE treated with ultrasound-facilitated, catheter-directed thrombolysis (USCDT) using the EKOS EkoSonic endovascular system with rt-PA (24 mg total; 2 mg/hr per catheter for up to 24 hours). Single-arm prospective study.

RV/LV ratio decreased from 1.55 ± 0.46 to 1.13 ± 0.37at 48 hours (mean change −0.42; 95% CI −0.35 to −0.48; p<0.001) — a 31% reduction. PA systolic pressure decreased 30%. Major adverse events occurred in 10 patients (6.7%), including 1 major bleeding event (0.7%). No intracranial hemorrhage.

Guideline relevance: Established the efficacy of USCDT for reducing RV overload in high-risk and intermediate-high-risk PE, informing CDT as an advanced therapy option in Category C3 and D patients per the 2026 guideline.

Piazza G, et al. JACC Cardiovasc Interv. 2015;8(10):1382-1392.

59 patients with intermediate-risk PE (RV/LV ratio ≥1.0) randomized to ultrasound-facilitated CDT (EKOS; 10 mg rt-PA per catheter; 10-15 mg total over 15 hours) plus heparin versus heparin alone. First randomized trial of CDT versus anticoagulation for intermediate-risk PE.

Mean RV/LV ratio change at 24 hours: −0.30 ± 0.20 with CDT vs −0.03 ± 0.16 with heparin(p<0.001). Clinical worsening (requiring escalation to rescue thrombolysis or embolectomy) occurred in 0 CDT patients vs 5 heparin patients (24%; p=0.02). No major bleeding events in either arm.

Guideline relevance:Provided first randomized evidence for CDT's superiority over anticoagulation for RV decompression, establishing the conceptual basis for catheter-directed therapy in intermediate-high-risk PE in the 2026 guideline.

Kucher N, et al. Circulation. 2014;129(4):479-486.

101 patients with intermediate-risk PE (RV/LV ratio ≥0.9) enrolled in a 4-arm dose-escalation trial using the EKOS catheter. Arms: 8 mg tPA/2 hours, 8 mg/4 hours, 12 mg/6 hours, or 24 mg/6 hours. Total tPA dose ranged from 16 to 24 mg (bilateral catheters).

All 4 arms showed significant RV/LV ratio reduction at 48 hours without significant differences between groups (mean reduction 0.38-0.42). Major bleeding occurred in 4% overall. No intracranial hemorrhage. Shorter infusion durations with lower tPA doses (8 mg/4 hours) achieved equivalent efficacy to longer, higher-dose protocols.

Guideline relevance: Supports use of reduced tPA doses (8-12 mg per catheter) for CDT in the 2026 advanced therapy framework, reducing bleeding risk without compromising efficacy for Category C3/D PE.

Tapson VF, et al. JACC Cardiovasc Interv. 2018;11(14):1401-1410.

800 patients with massive (21.6%) or submassive (78.4%) PE treated with the EKOS ultrasound-facilitated CDT system across 63 U.S. sites, including centers with and without formal PERT programs. Prospective, multicenter registry.

In-hospital mortality: 2.9% (5.7% massive, 0.8% submassive). Major bleeding: 1.4%. Intracranial hemorrhage: 0.4%. RV/LV ratio improved from 1.30 at baseline to 0.91 at 48 hours. Dyspnea and tachycardia resolved in the majority of patients within 24 hours. PERT activation was associated with shorter time to therapy and numerically lower in-hospital mortality.

Guideline relevance: Largest real-world CDT registry providing safety and effectiveness data to support catheter-directed therapy in Category C3, D, and E patients, with PERT data supporting formal PERT endorsement in 2026.

Piazza G, et al. JACC Cardiovasc Interv. 2015;8(10):1382-1392 (FLASH interim). Updated registry: 2022.

3,465 patients with suspected PE prospectively enrolled across 12 Dutch hospitals to validate the YEARS algorithm: three dichotomous items (DVT signs, hemoptysis, PE most likely diagnosis) combined with D-dimer thresholds of 1,000 μg/L (zero YEARS items) or 500 μg/L (any YEARS item positive).

PE was excluded in 1,650 patients (48%) without CTPA using the YEARS algorithm, compared with 34% using the conventional Wells-plus-D-dimer strategy — an absolute increase of 14% in CTPA-sparing. The 3-month VTE event rate among patients in whom PE was excluded was 0.61% (95% CI 0.36-0.96), confirming safety.

Guideline relevance: Directly supports the 2026 Class 2a endorsement of the YEARS algorithm with a D-dimer threshold of 1,000 μg/L for patients with zero YEARS criteria, reducing unnecessary CTPA radiation exposure.

van der Hulle T, et al. Lancet. 2017;390(10091):289-297.